Clinical trials: Breast Cancer, Metastatic
Cancer
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Diarrhoea is the most commonly reported adverse event (AE) associated with Lapatinib treatment, and is also commonly associated with Capecitabine treatment.
- Trial name
- NCT02294786
- Testing
- Lapatinib, Capecitabine, Octreotide
- Where
- 17 sites in Czechia, Israel and 3 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Metastatic
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
This is a multicenter, randomized, 2 arm, open label, phase II study. It is designed to compare the efficacy and safety of abemaciclib combined with ET (letrozole or fulvestrant) versus a short course with induction chemotherapy…
- Trial name
- ABIGAIL (NCT04603183)
- Testing
- Abemaciclib, Paclitaxel, Letrozole
- Where
- 31 sites in Italy, Portugal and 1 more
- Volunteers
- 162 people
- Sponsor
- MedSIR
Breast Cancer
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with…
- Trial name
- EMILIA (NCT00829166)
- Testing
- Trastuzumab emtansine, Lapatinib, Capecitabine
- Where
- 323 sites in United States, Bosnia and Herzegovina and 25 more
- Volunteers
- 991 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Metastasis
Study of GPX-100 in the Treatment of Metastatic Breast Cancer
The purpose of this early Phase II multicenter trial is to determine the objective clinical response to GPX-100, an anthracycline similar to doxorubicin, in up to 40 patients with newly diagnosed metastatic breast cancer.
- Trial name
- NCT00123877
- Testing
- GPX-100 (13-deoxydoxorubicin)
- Where
- 3 sites in United States, Bulgaria
- Volunteers
- 40 people
- Sponsor
- Gem Pharmaceuticals
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery.
- Conditions
- Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT02658812
- Testing
- Laboratory Biomarker Analysis, Talimogene Laherparepvec
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
This study is being done to see how safe the combination of eribulin and carboplatin is and if it will work to help people with advanced breast cancer. Eribulin and carboplatin are both chemotherapy drugs.
- Trial name
- NCT01795586
- Testing
- Eribulin, Carboplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and…
- Conditions
- Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT03281902
- Testing
- Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Breast Neoplasms
Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients
Research purpose: Lymphedema is a very common complication in breast cancer patients. However, since there is currently no curable treatment, it is important to prevent and reduce the severity of lymphedema.
- Trial name
- NCT06421285
- Testing
- Aerobic exercise, Strength training, Flexibility exercise
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Asan Medical Center
Depression, Stage I Breast Cancer
Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer
RATIONALE: Chemotherapy may affect various factors that can lead to weight gain. PURPOSE: Clinical trial to evaluate factors that may affect weight gain in women receiving adjuvant chemotherapy for stage I, stage II, or stage…
- Conditions
- Depression, Stage I Breast Cancer, Stage IIIA Breast Cancer, Nutrition
- Trial name
- NCT00019643
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Breast Cancer
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
The purpose of this study is to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), in HER2-overexpressed recurrent stage IV breast cancer patients who received at least 2 prior HER2-directed…
- Trial name
- NCT02418689
- Testing
- NOV120101 (Poziotinib)
- Where
- 7 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Metastatic Breast Cancer
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Aromatase inhibitor (AI) + CDK4/6 inhibitor is settled down as the standard first line therapy for HR+/HER2- metastatic breast cancer and all three CDk4/6 inhibitors, palbociclib, ribociclib, and abemaciclib are currently…
- Trial name
- NCT05816655
- Testing
- Fulvestrant plus AI plus ribociclib, AI plus ribociclib
- Where
- 2 sites in South Korea
- Volunteers
- 202 people
- Sponsor
- Korea University Guro Hospital
Breast Cancer, Lung Cancer
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00059943
- Testing
- docetaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis
Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study
non-intervention、real world study； Effect of timing and regular treatment of zoledronic acid on the incidence of SREs in breast cancer patients
- Trial name
- NCT05480189
- Testing
- Non-intervention
- Volunteers
- 1,000 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after treatment of an aromatase inhibitor.
- Trial name
- BETTER (NCT02910050)
- Testing
- Bicalutamide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Xu fei
Metastatic Breast Cancer
Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer
In this "randomised Phase II trial" all patients will receive carboplatin, with half randomly selected to receive ZD4054. The other half to also receive a dummy pill or placebo, this is so that we can accurately assess how much…
- Trial name
- PLANET (NCT01134497)
- Testing
- ZD4054
- Where
- United Kingdom
- Sponsor
- Cardiff University
Breast Cancer
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00085020
- Testing
- trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, HER2 Negative Breast Cancer
Shared Decision Making for Patients With HER2-negative Metastatic Breast Cancer (SDM-01)
Background and Purpose: Deciding on the best treatment for HER2-negative metastatic breast cancer (MBC) is a complex process. Patients often have unique values and preferences regarding their care and quality of life.
- Conditions
- Breast Cancer, HER2 Negative Breast Cancer, Metastatic Breast Cancer
- Trial name
- SDM-01 (NCT07578415)
- Testing
- Shared Decision Making (SDM) Support Program
- Volunteers
- 120 people
- Sponsor
- Federico II University
Triple-negative Breast Cancer
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
This is an open-label, phase Ib/II, multi-center study to evaluate efficacy and safety of KN046 alone or in combination with nab-paclitaxel in subjects with locally advanced unresectable or metastatic triple negative breast…
- Trial name
- NCT03872791
- Testing
- KN046, Nab-paclitaxel
- Where
- 12 sites in China
- Volunteers
- 52 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.